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Introduction
In 2004 we established a formal clinical service for
patients with hereditary periodic fever syndromes
(HPFS). Patients are either referred directly for clinical
evaluation, or undergo initial genetic screening on
receipt of blood or DNA sample and clinical details via
our secure online request procedure: http://www.ucl.ac.
uk/medicine/amyloidosis/nac/genetic_testing
Objectives
To evaluate eight years experience of a dedicated fever
clinic and associated laboratory service at the National
Amyloidosis Centre.
Methods
Between 2004 and 2009 the basic genetic screen encom-
passed FMF gene MEFV exons 2 and 10; TRAPS gene
TNFRSF1A exons 2-6; MKD gene MVK exons 9 and 11
and CAPS gene NLRP3/CIAS1 exon 3. When deemed
appropriate, these tests were extended to additional exons
on a case by case basis. From 2010 additional genes were
added to our repertoire: NOD2 (exons 2 and 4) associated
with Crohn’s Disease and Blau Syndrome; NLRP12 (exons
2 and 3) associated with familial cold autoinflammatory
syndrome 2 and IL36RN (exons 2-5) associated with
DITRA.
In each case the specific analyses were determined by
the NAC physicians after clinical assessment or on the
review of information provided by the external clinician.
Results
Since January 2005, 3063 patients have undergone
genetic screening at the NAC; 996 were assessed directly
at the fever clinic (33%), and blood or DNA were received
on a further 2067 (67%). MEFV was most frequently
requested (75%), followed by TNFRSF1A (58%), MVK
(42%) and NLRP3 (29%), other genes accounted for 6%.
Genetic variants were identified in 1048 patients
(34%): 627 (60%) had an amino acid variation in MEFV
(56% had a single variant including 34% who had
E148Q, 33% were compound heterozygotes and 11%
homozygotes). TNFRSF1A variants were found in 133
cases (13%); MVK in 74 (7%) (in 58% we were unable to
detect a second variant despite screening of all exons);
NLRP3 in 103 (16%) and NOD2 in 46 (4%). In 19
patients we identified genetic aberrations in more that
one HPFS gene. 28 novel variants were discovered: 9 in
NLRP3; 6 in TNFRSF1A; 7 in MVK; 5 in MEFV and 1
in NOD.
Conclusion
Since creation of the HPFS clinical service in 2004,
demand for genetic testing has grown substantially,
including a 125% increase in referrals during the past year.
In many cases two or more HPFS genes were screened.
We found 1234 genetic variants in 1048 screened cases, of
which nearly 40% accounted for low penetrance sequence
variants of undetermined significance including MEFV
E148Q, TNFRSF1A R92Q and P46L, MVK S52N and
NLRP3 V198M and Q703K. Interestingly we found 19
patients with variations in more than one HPFS gene. In
16 of these we were able to make a clinical diagnosis:
7 had CAPS; 5 MKD; 3 TRAPS and 1 FMF; the remaining
3 had atypical autoinflammatory phenotypes.
An overlap in clinical features between different HPFS
highlights the importance of genetic testing in providing
accurate diagnosis, leading to appropriate treatment and
improvement of quality of life.
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